ARCHIVES

FDA Grants Priority Review To Two Drugs in NSCLC

This article is from The Cancer Letter archive.

Vol. 36 No. 2 | February 22, 2013

Download PDF Visit The Full Archive

Related Articles

NCI Calls Fisher “A Dominant Force” In Breast Cancer

September 5, 1997

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

January 14, 2005

Blood Cancers Advocacy Groups Seek DOD And NCI Funds, Medicare Coverage.

July 6, 2001

Starr Foundation Gives $100 Million To Form Cancer Consortium.

September 29, 2006

Pooled Analysis of Two LUX-Lung Trials Shows Prolonged Survival with Afatinib

June 27, 2014

Nutrition May Get An Extra 44 Million In FY 1979; Program Announcement Describes Opportunities

September 22, 1978